FLGT - CIK 0001674930
Fulgent Genetics, Inc. trades as FLGT. In its fiscal 2025 annual report the company posted revenue of $322.67M, up 13.8% from the prior year and net income of -$60.51M. This page tracks Fulgent Genetics, Inc. through 636 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 9 fiscal years Fulgent Genetics, Inc.'s revenue grew from $18.28M to $322.67M, a compound annual growth rate of 37.6%. Net profit margin expanded from -29.3% to -18.8% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13D/A | - | 2026-05-27 |
| Insider trade | 4 | 2026-05-27 |
| Major company event | 8-K | 2026-05-21 |
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
| Employee stock plan | S-8 | 2026-05-14 |
| Major company event | 8-K | 2026-05-14 |
The largest companies sharing Fulgent Genetics, Inc.'s SEC industry classification (services-medical laboratories).
Fulgent Genetics, Inc. reported revenue of $322.67M for fiscal year 2025, an increase of 13.8% year over year.
In its latest fiscal year Fulgent Genetics, Inc. reported a net loss of $60.51M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.